Department of Clinical Nutrition, School of Nutrition & Food Science, Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran; Halal Research Center of IRI, FDA, Tehran, Iran.
Department of Community Nutrition, School of Nutrition and Food Science, Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Clin Nutr. 2021 Jul;40(7):4662-4673. doi: 10.1016/j.clnu.2021.05.027. Epub 2021 Jun 8.
We conducted a systematic review and meta-analysis to evaluate evidence from randomized controlled trials (RCTs) documenting the effectiveness of supplementation with pro-/synbiotics versus placebo controls on anthropometric and metabolic (glucoregulatory status, lipid profile) indices in adults with metabolic syndrome (MetS).
Databases of MEDLINE, Scopus, Embase, Web of Science, and Cochrane Library were searched through March 2020 to identify eligible RCTs evaluating the effects of pro-/synbiotic consumption in adults (≥18 years) with MetS. Mean differences (MDs) and 95% confidence intervals (CIs) were pooled using random-effects models.
Ten eligible publications (9 RCTs, n = 344 participants) were included. Supplementation with pro-/synbiotics reduced total cholesterol (TC) in adults with MetS versus placebo (MD: -6.66 mg/dL, 95% CI: -13.25 to -0.07, P = 0.04, I = 28.8%, n = 7), without affecting weight, body mass index, waist circumference, fasting blood sugar, homeostasis model assessment for insulin resistance, insulin, triglyceride, low-density lipoprotein cholesterol, or high-density lipoprotein cholesterol (P > 0.05).
Pro-/synbiotic consumption may be beneficial in reducing TC levels in adults with MetS. However, our observations do not support the effectiveness of pro-/synbiotics consumption on other anthropometric or metabolic outcomes of MetS. Further investigations with larger sample sizes are required to confirm these findings.
我们进行了系统评价和荟萃分析,以评估随机对照试验(RCT)的证据,这些试验记录了补充益生菌/合生剂与安慰剂对照在代谢综合征(MetS)成年人中对人体测量学和代谢(血糖调节状态、血脂谱)指标的有效性。
通过 MEDLINE、Scopus、Embase、Web of Science 和 Cochrane 图书馆数据库检索,截至 2020 年 3 月,以确定评估益生菌/合生剂在代谢综合征成年人(≥18 岁)中消费效果的合格 RCT。使用随机效应模型汇总平均差异(MD)和 95%置信区间(CI)。
纳入了 10 篇合格文献(9 项 RCT,n=344 名参与者)。与安慰剂相比,补充益生菌/合生剂可降低代谢综合征成年人的总胆固醇(TC)(MD:-6.66mg/dL,95%CI:-13.25 至-0.07,P=0.04,I=28.8%,n=7),而不会影响体重、体重指数、腰围、空腹血糖、胰岛素抵抗评估的稳态模型、胰岛素、甘油三酯、低密度脂蛋白胆固醇或高密度脂蛋白胆固醇(P>0.05)。
益生菌/合生剂的消费可能有益于降低 MetS 成年人的 TC 水平。然而,我们的观察结果并不支持益生菌/合生剂消费对 MetS 的其他人体测量学或代谢结果的有效性。需要进一步进行更大样本量的研究来证实这些发现。